SLC5A2 and hydrops fetalis: Surprisingly, several large-scale randomized clinical trials have demonstrated that SGLT2 inhibitors reduce CV mortality dramatically, improve CV outcomes, and reduce HF hospitalization in T2DM patients whether they have pre-existing CV disease or not (17–22).